OrbiMed’s Abbott ABT Stock Holding History

OrbiMed’s Portfolio ABT Stock Details ABT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$20.1M	–	108
2025 Q3	$20.1M	Buy	+150,000	New	+$19.7M	0.47%	53

Other funds holding ABT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's ABT Position: Q1 2020 in Review

OrbiMed sold out of Abbott (ABT) in Q1 2020, closing a stake of 715,100 shares — an estimated $62.1M sold.

OrbiMed first reported a position in ABT in Q2 2013 and held it in 23 quarters. The position peaked at $78.9M in Q2 2019. 2,145 funds tracked by Wall St. Rank hold ABT as of Q1 2020.

OrbiMed reported no remaining Abbott position as of Q1 2020 after selling out during the quarter.
OrbiMed sold 715,100 Abbott shares in Q1 2020, an estimated $62.1M.
OrbiMed first reported a position in Abbott in Q2 2013 and held it in 23 quarters.
OrbiMed's Abbott position peaked at $78.9M in Q2 2019.
2,145 funds tracked by Wall St. Rank held Abbott as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.